On-demand: This is a recorded version of the live webinar.
This webinar will cover key topics, including:
- China regulatory system
- Clinical trial approval and latest development with subsequent impact
- Priority review with subsequent impact on clinical trial and market authorisation approval
- Draft/new drug registration regulation and its impact
- Draft/new chemical drug variation guidelines
- Life cycle management in china
- Differences between Europe and China
You will learn about
- China regulatory framework for clinical trial approval, MAA data requirements and post approval
- The latest China regulatory updates
Who should attend
This webinar will be suitable for all individuals as it will start with the basic introduction of the China regulatory framework, then focus on the key elements which are very different from the EU regulatory practices.
The newly draft/final versions of the key regulatory guidelines will be interpreted to provide you with the most updated regulatory information and include its impact on China and the global pharmaceutical industry.
Why you should attend
This webinar will not only provide you with the latest regulatory developments in China, it will explain the reasons and the impacts of the changes. This will provide you with the essential updated tools for forming your China and Global Regulatory strategies.
The China regulatory framework is going through a lot of dramatic changes since 2015, with the rapid expending of China healthcare spending, this update is essential.
You may also be interested in:
CPD
This course offers 1 CPD hour for successful completion, to learn about why CPD is important visit the Lifelong Learning page.
Cost of the webinar
Members: £75.00 + VAT
Non members: £95.00 + VAT
All prices are in pounds sterling and are exclusive of VAT
To register, please log in or create an account
Please read the training terms and conditions before booking this course. By booking a place on this course you are agreeing to the training terms and conditions.